A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655
Diane EganZOLL Medical Corporation+1 (978) email@example.com
FOR IMMEDIATE RELEASE
Friday, March 04, 2005 – CHELMSFORD, MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, will display its advanced products in Booth #2981 at the American College of Cardiology’s 54th Annual Scientific Sessions. ZOLL also will unveil its latest automated external defibrillator (AED) for professional first responders, the AED Pro™, which extends ZOLL’s AED product line. Attended by more than 16,000 medical professionals, the sessions will take place March 6 through March 9 in Orlando, Florida.“To improve resuscitation outcomes, we believe additional technology must become available as an adjunct to defibrillation efforts,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “Our new AED Pro™, CodeNet™, and the AutoPulse™ Non-invasive Cardiac Support Pump are examples that reinforce our commitment to advance the practice of resuscitation, and help clinicians save lives that would otherwise be lost.”
The AED Pro offers advanced capabilities for Basic Life Support (BLS) users. It also provides AED capability with manual override access for Advanced Life Support (ALS) users. The AED Pro features a high-quality display for ECG monitoring with standard ECG electrodes. It is the only professional defibrillator to use ZOLL’s CPR-D-padz™ electrode that measures the rate and depth of chest compressions during CPR, and provides visual and audible feedback on performance.
• ZOLL CodeNet is the first software system for hospital code response teams to document, manage, and review cardiac arrest event and resuscitation data. It provides efficiencies in data capture, event-time synchronization, and reporting. It is the only system that time stamps logged events and synchronizes these times with defibrillator data, providing clinicians with a complete and accurate timeline of an entire cardiac arrest event.• The AutoPulse™ Non-invasive Cardiac Support Pump provides the potential of normal blood flow levels during sudden cardiac arrest1,2. It is comprised of a backboard and a simple load-distributing LifeBand™ that fastens across a patient’s chest and moves more blood, more effectively,1,2,3,4,5 than human hands can possibly do. There is a growing body of third-party research supporting the benefits of the AutoPulse.• The ZOLL M Series™ is the monitor/defibrillator of choice at top cardiac hospitals. M Series customers can configure the device to include multiple monitoring parameters and operating modes. The U.S. Food and Drug Administration (FDA) cleared ZOLL’s Rectilinear Biphasic™ waveform (RBW), which is used in all ZOLL defibrillators, to be labeled as clinically superior to monophasic defibrillators for the conversion of ventricular fibrillation in high impedance patients, and for cardioversion of atrial fibrillation.• The WCD 3000S Patient Management System allows in-hospital patients who are at high risk of ventricular fibrillation and ventricular tachycardia to be monitored constantly and receive an immediate defibrillating shock, if needed. It provides patients with unhindered mobility, and clinicians with the assurance of high-quality care, regardless of the patient’s location or need to ambulate.• The ZOLL AED Plus™ can help infrequent rescuers administer defibrillation and CPR in non-clinical areas of the hospital, or as part of community outreach programs. It is the only AED that helps rescuers achieve the recommended rate and depth of chest compressions during CPR. The AED Plus converts the compression data from the CPR-D-padz and provides visual and audible feedback that tells a rescuer, “Push harder” or “Good compressions.”
ZOLL Medical Corporation (NASDAQ: ZOLL) is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that can help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical data.ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, The Netherlands, Australia, and Austria. With direct operations, international offices, and business partners in all of the world’s major markets, ZOLL markets and sells its products in more than 140 countries.Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, potential sales levels, its ability to differentiate its products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the ability of the ZOLL sales force to market successfully multiple resuscitation products, and those factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-Q, which was filed with the SEC on February 11, 2005.© 2005 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus, AED Pro, AutoPulse, CodeNet, LifeBand, and M Series are trademarks of ZOLL Medical Corporation. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.*This software is compatible with the NRCPR. This statement does not convey or imply the American Heart Association endorsement, or suggestion of superiority of this or any product or equipment. Additional subscription to the NRCPR is required.1 Halperin HR et al. Improved hemodynamics with a novel chest compression device during a porcine model of cardiac arrest. Circulation. 2002:106(19)(Suppl II):538.2 Ikeno F et all. Improved survival with a novel chest compression device during a porcine model of cardiac arrest. Circulation. 2003;108(17)(suppl IV):381.3 Timerman S et al. Improved hemodynamic performance with a novel chest compression device during treatment of in-hospital cardiac arrest. Circulation. 2004;61:273-280.4 Ornato JP et al. Improvement in field return of spontaneous circulation using circumferential chest compression cardiopulmonary resuscitation. Prehospital Emergency Care. 9(1):104.5 Casner M et al. The impact of a new CPR assist device on rate of return of spontaneous circulation in out-of-hospital cardiac arrest. Prehospital Emergency Care. 2005;9(1):61-67.